Forensic Intelligence Report

EXTREMELY HIGH RISK

Paul P. Edalat

Pharmaceutical CEO charged by SEC with $6.6M offering fraud and self-dealing

Subject

Paul P. Edalat — CEO, Vivera Pharmaceuticals, Inc.

Jurisdictions

California, USA (Central District)

Investigation Period

May 2018 – Present

Methodology

Analysis of SEC filings, federal court records, and adverse media coverage

8:22-cv-01792

Active Federal Case

$6.6M

Alleged Fraud Total

U.S. SEC

Regulator

C.D. Cal.

Jurisdiction

Verified Records

SEC Allegations:6

Entities Charged:3

Securities Law Violations Cited:7

Risk Signals Identified:12

Core Risk Tags

SEC EnforcementOffering FraudSelf-DealingPharmaceuticalMisappropriationConflict of InterestFederal LitigationOfficer & Director Bar Sought

Jump to Section

Executive Summary

High-level risk overview and investigation findings

Paul P. Edalat, an Orange County, California-based pharmaceutical executive, is the controlling shareholder and CEO of Vivera Pharmaceuticals, Inc., and concurrently controlling shareholder of EFT Global Holdings, Inc. d/b/a Sentar Pharmaceuticals. In September 2022, the U.S. Securities and Exchange Commission filed a civil enforcement action in the Central District of California alleging that Edalat orchestrated a multi-year offering fraud raising approximately $6.6 million from investors through private placements of Vivera stock between May 2018 and June 2020.

The SEC's complaint asserts that Edalat failed to disclose his dual control of both the issuer and the ostensible licensor of Vivera's core sublingual drug-delivery technology, enabling the round-tripping of approximately $4.51 million in purported licensing fees from Vivera to Sentar and ultimately into accounts personally controlled by Edalat. Funds were allegedly used to finance personal luxury expenditures, including a $425,000 vehicle and down payments on two homes.

Key Indicators

Risk Classification

Extreme

Case Status

Active

Investor Capital at Issue

$6.6M

Alleged Misappropriation

$4.51M

Officer/Director Bar Sought

Yes

Self-Reported Defenses

Disputed

Identity & Background

Profile, role, and controlling interests

▸Full name: Paul P. Edalat
▸Primary role: Chief Executive Officer, Vivera Pharmaceuticals, Inc.
▸Base of operations: Orange County, California, USA
▸Entity type: Individual (corporate principal)

Analyst Note: Edalat's overlapping fiduciary roles across the issuer (Vivera) and the licensor (Sentar) sit at the heart of the SEC's allegations. The structural conflict — where the same individual controls both sides of a multi-million-dollar related-party licensing arrangement — created the conditions for the alleged misappropriation that forms the core of the federal complaint.

Corporate Network

Vivera Pharmaceuticals and Sentar Pharmaceuticals

Vivera Pharmaceuticals, Inc.

The issuer entity at the center of the alleged offering fraud. Based in Orange County, California, Vivera raised capital from investors via private placements of its stock and represented to investors that it held an exclusive global license to certain sublingual drug-delivery technology. Vivera is named as a defendant in the SEC's 2022 complaint.

EFT Global Holdings, Inc. d/b/a Sentar Pharmaceuticals

The ostensible licensor that purportedly granted Vivera rights to the sublingual drug-delivery technology. Sentar received approximately $4,510,000 in purported licensing fees from Vivera, which the SEC alleges were then transferred onward into accounts personally controlled by Edalat. Like Vivera, Sentar is named as a defendant.

Related-Party Architecture

Both Vivera and Sentar are alleged to be under the common control of Paul P. Edalat. The SEC alleges this common control was not disclosed to Vivera investors, who were therefore unaware that licensing payments routed from Vivera to Sentar effectively flowed to the issuer's own controlling shareholder.

Personally Controlled Accounts

The complaint identifies multiple accounts under Edalat's personal control that received funds originating with Vivera investors via the Sentar licensing channel. These accounts allegedly funded personal expenditures rather than the legitimate operating expenses or licensor obligations represented to investors.

Corporate Entity Network

Click nodes or edges to explore relationships

Entity Status

Active

Dissolved

Deregistered

Unknown

Relationship Type

directorship

address

operational

analytics

Self-Dealing Network

The corporate architecture forms a closed loop: investor capital enters Vivera via private placements, flows to Sentar as licensing fees, and is then transferred to accounts controlled by the same individual — Edalat — who controls both the payor and the recipient. The undisclosed nature of this loop is a central pillar of the SEC's fraud allegations.

Issuer footprint identified

Vivera Pharmaceuticals' public-facing channels anchor the offering.

0/ 4 domains revealed

High Risk

Medium

Low

Scroll to reveal the network

OSINT Finding — Verified

The Vivera and Sentar online presences are connected through Edalat's common control — a structural fact not disclosed to investors during the capital raise.

Source Triangulation·Google Analytics Tag

Authoritative reporting from the SEC and major financial-legal outlets provides convergent, independently sourced documentation of the allegations.

Regulatory Exposure

SEC enforcement action and securities law violations

SEC Civil Action (2022)

▸Case: SEC v. Vivera Pharmaceuticals, EFT Global Holdings d/b/a Sentar, and Paul P. Edalat
▸Court: U.S. District Court, Central District of California
▸Case No.: 8:22-cv-01792
▸Filed: September 30, 2022
▸Status: Active / Pending

Statutory Violations Alleged

▸Securities Act § 17(a)(1) — anti-fraud
▸Securities Act § 17(a)(2) — material misstatements/omissions
▸Securities Act § 17(a)(3) — fraudulent course of business
▸Exchange Act § 10(b) and Rule 10b-5(a), (b), (c)

Remedies Sought by SEC

▸Permanent injunctions against future violations
▸Disgorgement of ill-gotten gains plus prejudgment interest
▸Civil monetary penalties
▸Conduct-based injunctions
▸Officer-and-director bar against Edalat

Additional Findings

Underlying Civil Litigation (License Dispute)

▸Vivera filed lawsuit in December 2018 challenging a third party's claim to the sublingual drug-delivery license
▸Vivera lost the lawsuit in May 2020, validating the third party's prior license rights
▸Existence and outcome of this dispute were allegedly not disclosed to investors during the offering period

Investigative Personnel (SEC)

▸Investigators: Robert Stillwell, Carol Kim
▸Investigation supervisor: Finola H. Manvelian (Los Angeles Regional Office)
▸Lead litigator: Stephen Kam
▸Litigation supervisor: Gary Leung

Regulatory Standards Comparison

Comparing U.S. Securities and Exchange Commission (Vivera Pharmaceuticals, Inc. / Paul P. Edalat's regulator) against tier-1 authorities. Higher bars indicate stronger investor protection.

SECPrimary Regulator

U.S. federal securities regulator with civil enforcement authority

Civil FraudAction Type

Anti-fraud provisions of the 1933 and 1934 Acts

5 CategoriesRemedies Sought

Injunctions, disgorgement, penalties, conduct bars, O&D bar

ActiveCase Status

Pending in U.S. District Court, C.D. Cal.

FCA
ASIC
CySEC
U.S. Securities and Exchange Commission (Vivera Pharmaceuticals, Inc. / Paul P. Edalat)

Tier-1 Regulators (Strong Protection)

U.S. Securities and Exchange Commission (Weak Oversight)

Chart shows normalized protection scores (0–100%) for comparison. Hover over bars for detailed explanations. Sources: FCA Handbook, ASIC RG 227, CySEC Circular C168, U.S. Securities and Exchange Commission regulations.

Investor Harm Assessment

Alleged losses and misappropriation pattern

Investors who participated in Vivera's private placements between May 2018 and June 2020 collectively contributed approximately $6.6 million on the basis of representations that the SEC alleges were materially false or misleading. Of those proceeds, approximately $4.51 million was transferred to Sentar as purported licensing fees and onward to accounts controlled by Edalat — representing the alleged direct misappropriation channel.

Alleged Misappropriated Spending

The SEC complaint identifies specific personal expenditures funded by allegedly misappropriated investor capital, including a $425,000 luxury automobile and down payments on two residential properties. These expenditures are inconsistent with the use-of-proceeds representations made to investors.

Concealed Material Risk

Investors were not informed of the active dispute over the validity of Vivera's claimed exclusive license. Sentar had allegedly previously conveyed the same license rights to a third party, creating an undisclosed encumbrance on what Vivera presented as its core asset. When Vivera lost the underlying license litigation in May 2020, the materiality of this omission was confirmed.

Conflict-of-Interest Exposure

Investors were not informed that Edalat controlled both Vivera and Sentar. As a result, they could not independently evaluate whether the $4.51 million in licensing fees represented arm's-length consideration or a self-dealing transfer. This omission deprived investors of the ability to assess the true risk and economic substance of their investment.

Total Reviews Analysed

Verified Testimonials

Aggregated investor and media-source complaints, 2020–2023

Investigation Period

Monthly Complaint Distribution

Withdrawal Issues

Hidden Fees

Manipulation

Misrepresentation

Testimonials

MisrepresentationSEC Litigation Release· 2022-09-30

"SEC alleges Vivera and Edalat made material misrepresentations regarding the exclusivity and validity of the company's core license."

Reported loss: $6.6M aggregate

ManipulationSEC Complaint· 2022-09-30

"Allegations that Edalat orchestrated round-tripping of investor funds through Sentar back into accounts he controlled."

Reported loss: $4.51M alleged diversion

MisrepresentationCompliance Week· 2022-10-05

"Coverage emphasized SEC findings of undisclosed conflicts of interest in the Vivera–Sentar arrangement."

Reported loss: Material omission

Hidden FeesBloomberg Law· 2023-01-15

"SEC seeking approximately $2.1 million in disgorgement from Edalat individually."

Reported loss: $2.1M disgorgement sought

Withdrawal IssuesFiercePharma· 2022-10-12

"Reporting on investor inability to recover capital amid ongoing federal litigation."

Reported loss: Recovery uncertain

Reputational and Recovery Outlook

Recovery prospects for affected investors depend on the outcome of the SEC's pending action and any related private litigation. The SEC is pursuing disgorgement and prejudgment interest, which — if obtained — may form a partial recovery pool. However, given the alleged dissipation of funds into personal assets, full restitution remains uncertain. The reputational impact on Edalat and his controlled entities is severe and ongoing, with adverse coverage across regulatory, legal, and pharmaceutical trade media.

Claims vs. Reality

Representations to investors versus SEC findings

All matters described as 'alleged' remain subject to adjudication in the U.S. District Court for the Central District of California. Defendants are presumed innocent of any unproven civil claims unless and until found liable by the court.

Investigation Timeline

Chronological sequence of material events

2024

2023

2022

2020

2019

2018

Risk Analysis

Multi-dimensional risk scoring

Multi-Dimensional Risk Radar

EXTREMELY HIGH

HIGH

MEDIUM

LOW

Overall Risk Classification

Cumulative exposure across regulatory, financial, governance, and reputational dimensions reflects a profile consistent with extreme counterparty and investor risk.

Regulatory & Legal

Financial Integrity

Governance & Operations

Reputation & Media

Regulatory & Legal

EXTREMELY HIGH

Active SEC fraud action with officer-and-director bar sought

Financial Integrity

EXTREMELY HIGH

Alleged misappropriation of $4.51M in investor-derived funds

Governance & Operations

EXTREMELY HIGH

Common control of issuer and licensor with undisclosed conflict

Reputation & Media

HIGH

Sustained adverse coverage across regulatory and pharmaceutical trade media

Risk Analysis Summary

Securities Fraud Exposure

EXTREME

Active SEC civil action alleging multi-year offering fraud raising $6.6M from private placement investors.

Misappropriation Risk

EXTREME

Alleged diversion of $4.51M in investor-derived funds via related-party licensing channel into personally controlled accounts.

Governance Failure

EXTREME

Undisclosed common control of issuer and licensor created structural conflict at the heart of the alleged fraud.

Disclosure Integrity

EXTREME

Material omissions alleged regarding both the conflict of interest and the contested validity of Vivera's core license.

Recovery Risk for Investors

HIGH

Funds substantially dissipated into personal assets; recovery depends on disgorgement outcomes and asset traceability.

Reputational Risk

HIGH

Sustained adverse coverage across regulatory, legal, and pharmaceutical trade media throughout 2022–2024.

Red Flags

Critical warning indicators

Regulatory

Financial

Operational

Reputation

Regulatory

Financial

Operational

Reputation

Investigative Gaps & Unknowns

The following gaps remain open. Additional OSINT collection or legal discovery may resolve them.

Final adjudication of SEC v. Vivera/Edalat remains pending; allegations have not been proven in court.

Asset traceability for the alleged $4.51M diversion has not been fully disclosed in public filings.

Recovery prospects for affected investors via disgorgement or parallel private litigation remain undetermined.

Edalat's nationality, date of birth, and full prior career history are not established in available public sources.

Status and substance of any ancillary state bar or business-dispute matters referenced in independent media remain unverified.

Whether parallel criminal investigation exists has not been confirmed in public regulatory or court records reviewed.

This report relies on publicly available regulatory filings, federal court records, and journalistic reporting current as of the analysis date. All allegations remain subject to defense, adjudication, and potential settlement.

Conclusion & Outlook

Paul P. Edalat presents an extreme-risk profile driven by an active U.S. SEC civil enforcement action alleging a $6.6 million offering fraud, undisclosed self-dealing through common control of Vivera Pharmaceuticals and Sentar Pharmaceuticals, alleged misappropriation of approximately $4.51 million in investor-derived funds, and concealment of a material dispute over Vivera's core licensed technology. The SEC's pursuit of an officer-and-director bar, conduct-based injunctions, disgorgement, and civil penalties signals the regulator's view of the matter as severe. Until the federal action is adjudicated or settled, any counterparty, prospective investor, or financial institution should treat exposure to Edalat or his controlled entities with heightened due diligence and active risk-mitigation protocols.

This report is an analytical synthesis of public records and media coverage. All matters described as 'alleged' are unproven and subject to ongoing litigation. Defendants are presumed innocent of any unproven civil claims unless and until found liable by a competent court. Nothing in this report constitutes legal advice or a definitive finding of wrongdoing.

Get Involved

We moderate comments to keep this a respectful and safe place. We have a zero-tolerance approach to user-to-user personal abuse. Please follow the house rules.

COMMENT

Participate in discussion, add context, and respond to this report.

TIPS AND EVIDENCE

Submit verified tips, supporting evidence, or additional intelligence.

CORRECTIONS

Request factual corrections or submit verifiable updates for this report.

* This discussion is moderated. Keep comments factual, relevant, and constructive. All submissions are reviewed before publication.

No comments yet. Be the first to comment!

AML Report

Paul Edalat

Executive Summary

Identity & Background

Corporate Network

Vivera Pharmaceuticals, Inc.

EFT Global Holdings, Inc. d/b/a Sentar Pharmaceuticals

Related-Party Architecture

Personally Controlled Accounts

Self-Dealing Network

Regulatory Exposure

Regulatory Standards Comparison

Investor Harm Assessment

Alleged Misappropriated Spending

Concealed Material Risk

Conflict-of-Interest Exposure

Reputational and Recovery Outlook

Claims vs. Reality

Vivera holds an exclusive global license to sublingual drug-delivery technology

Licensing arrangement between Vivera and Sentar is an arm's-length transaction

Investor capital used for legitimate corporate purposes

Vivera operates a legitimate, growing pharmaceutical business

SEC action is politically motivated (defense position)

Investigation Timeline

Adjacent State Bar Complaint Reporting

Litigation Proceeds

SEC Files Civil Complaint

Defense Public Response

Vivera Loses License Litigation

Offering Period Ends

SEC Investigation Phase

Continued Capital Raising

Vivera Begins Private Placement Offerings

Vivera Sues Over License Rights

Risk Analysis

Risk Analysis Summary

Securities Fraud Exposure

Misappropriation Risk

Governance Failure

Disclosure Integrity

Recovery Risk for Investors

Reputational Risk

Red Flags

Active SEC Fraud Action

Officer-and-Director Bar Sought

Multi-Year Offering Fraud Allegation

Multiple Stacked Securities Law Violations

Alleged Misappropriation of Investor Funds

Lavish Personal Expenditures from Alleged Misappropriation

Alleged Self-Dealing via Related-Party Licensor

Concealed License Validity Dispute

Loss of Underlying License Litigation

Adverse Multi-Source Media Coverage

Investigative Gaps & Unknowns

Conclusion & Outlook

Risk Index

Sherlock

Brian Castellano

Michelle Donovan

Diane Buchanan

Verification Snapshot

ANONYMOUS TIPS

3

CORRECTIONS

1

PUBLISHED DATE

Apr 29, 2026

LAST MODIFIED

Apr 29, 2026

Get Involved

COMMENT

TIPS AND EVIDENCE

CORRECTIONS

Have credible information, documentation, or source material relevant to a high-risk entity?

BitFinex

Entity Type

Jurisdiction

Known For

Parent Company

IronFX